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Summary 
Experimental autoimmune encephalomyelitis (EAE) is the rodent model of multiple 
sclerosis (MS), a chronic autoimmune neuroinflammatory disease that has a devastating 
impact on various neurological functions of the patients. The hallmarks of both, MS and EAE, 
are neuroinflammation, demyelination and neuroaxonal degeneration. Various types of 
lymphoid and myeloid cells were shown to infiltrate the central nervous system and to 
participate in disease pathology. However, the role of eosinophil granulocytes has been less 
explored thus far. An early study showed that eosinophils infiltrate into the spinal cord of EAE 
mice and suggested their role in the disease progression. Recently, it was reported that 
eosinophils can play a protective role against EAE when mice are treated with an extract 
from helminths. Furthermore, it was shown that EAE development is not altered in mice 
deficient for interleukin-5, an important eosinophil pro-survival factor. Taken together, the role 
of eosinophils in EAE is currently unclear and needs to be investigated in detail. 
In the present study, we use the active model of EAE, whereby we immunized the 
C57BL/6 mouse strain with MOG35-55 peptide emulsified in the complete Freund’s adjuvant, in 
order to study a possible contribution of eosinophils to the disease pathology. Using the flow 
cytometry and RT-qPCR analysis of the spinal cord, we show that eosinophils infiltrate into 
the tissue in the course of EAE. The infiltration is likely driven by eosinophil chemoattractants, 
such as eotaxin-1, as the concentration of the latter was increased in the spinal cord during 
EAE, as shown on mRNA and protein level. Moreover, detailed flow cytometry analysis of 
spinal cord eosinophils revealed that they show signs of activation, namely an increase in 
CD11b and decrease in CCR-3 surface expression. Furthermore, we observed signs of 
degranulation of spinal cord eosinophils in EAE which was measured as a decrease of the 
side scatter parameter and an upregulation of CD63 surface expression. These data suggest 
a potential role of eosinophils in the pathology of EAE. In order to elucidate whether 
eosinophils are important for the disease development, eosinophil-deficient mice were 
subjected to EAE and the clinical development of the disease was observed. For this 
purpose, we used two independent models of eosinophil deficiency - ∆dblGATA1 and 
interleukin-5-depleted mice. ∆dblGATA1 mice are a genetically manipulated mouse strain 
bearing a deletion in GATA1 promoter that causes a specific depletion of eosinophils. 
Interestingly, clinical development of EAE was not affected in these mice when compared to 
their wild-type controls. As a next step, we depleted eosinophils by injecting wild-type mice 
with an antibody against the eosinophil pro-survival factor interleukin-5 in order to reduce 
eosinophil numbers in the effector phase of EAE. In accordance with the result from the 
experiment with ∆dblGATA1 mice, EAE progression was not altered in the eosinophil-
depleted mice when compared to mice that were injected with an isotype control antibody. 
Further, we analyzed the neuroinflammation and demyelination in the spinal cord of 
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∆dblGATA1 mice subjected to EAE. Specifically, the infiltration of inflammatory cell 
populations, including CD4 and CD8 T cells, neutrophils and macrophages, was assessed by 
flow cytometry. In agreement with the unchanged clinical EAE development, inflammatory 
cell infiltration was not affected in ∆dblGATA1 mice. Furthermore, we analyzed expression of 
pro-inflammatory cytokines in the spinal cord of ∆dblGATA1 mice subjected to EAE in order 
to better characterize the inflammatory status. No significant changes were detected further 
confirming that eosinophils do not contribute to neuroinflammation in EAE. Finally, we 
assessed the demyelination in the spinal cord of ∆dblGATA1 EAE mice using luxol fast blue 
staining to detect myelin. In accordance with the unaffected clinical development and 
inflammatory status, we did not observe any difference in the spinal cord demyelination in 
∆dblGATA1 mice when compared to their wild-type littermates.  
Taken together, although eosinophils infiltrate into the spinal cord of EAE mice and are 
activated and degranulate therein, they are dispensable for EAE development. 
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Zusammenfassung 
Experimentelle Autoimmunencephalomyelitis (EAE) ist das Nagetiermodell für Multiple 
Sklerose (MS), eine chronische, neuroinflammatorische Autoimmunerkrankung, welche 
drastische Auswirkungen auf zahlreiche neurologische Funktionen des Patienten hat. 
Charakteristisch für beide, MS und EAE, sind Neuroinflammation, Demyelinisierung und 
neuroaxonale Degeneration. Es wurde gezeigt, dass verschiedene Typen lymphoider und 
myeloider Zellen das zentrale Nervensystem infiltrieren und zur Pathologie der Krankheit 
beitragen. Die Rolle von eosinophilen Granulocyten dabei wurde bis jetzt jedoch noch nicht 
genau untersucht. Eine frühe Studie zeigte, dass Eosinophile das Rückenmark von EAE-
Mäusen infiltrieren und legt nahe, dass sie eine Rolle beim Fortschreiten der Krankheit 
spielen. Kürzlich wurde berichtet, dass Eosinophile eine schützende Rolle gegen EAE 
spielen, wenn Mäuse mit einem Helminthextrakt behandelt wurden. Außerdem wurde gezeigt, 
dass sich der Verlauf von EAE in Interleukin-5 – ein wichtiger Überlebensfaktor für 
Eosinophile -defizienten Mäusen nicht verändert. Insgesamt, ist die Rolle von Eosinophilen in 
EAE derzeit unklar und bedarf detaillierter Untersuchung. 
In der vorliegenden Studie nutzen wir das aktive EAE-Modell, wobei wir Mäuse des 
C57Bl/6 Stammes mit MOG35-55 Peptid emulgiert in Komplettmedium Freund’s Adjuvant 
injizieren, um die mögliche Beteiligung von Eosinophilen am pathologischen Verlauf von EAE 
zu erforschen. Mit Hilfe von Durchflusszytometrie und RT-qPCR Analyse des Rückenmarks 
zeigen wir, dass im Verlauf von EAE Eosinophile in das Gewebe infiltrieren. Die Infiltration 
wird wahrscheinlich durch chemische Lockstoffe von Eosinophilen, wie Eotaxin-1, 
angetrieben, da dessen Konzentration im Rückenmark auf mRNA- und Proteinebene 
während der EAE erhöht war. Weiterhin legte detaillierte Durchflusszytometrieanalyse von 
Eosinophilen des Rückenmarks dar, dass diese Zeichen von Aktivierung aufweisen, 
namentlich ein Anstieg in CD11b und eine Abnahme von CCR-3 Oberflächenexpression. 
Außerdem beobachteten wir Anzeichen von Degranulation der Rückenmarkseosinophilen 
bei EAE, was über eine Abnahme des Seitwärtsstreulichtparameters und einer 
Hochregulierung von CD63 Oberflächenexpression bestimmt wurde. Diese Daten legen eine 
potentielle Rolle von Eosinophilen in der Pathologie von EAE nahe. Um festzustellen, ob 
Eosinophile wichtig für das Fortschreiten der Krankheit sind, wurde EAE in Eosinophil- 
defizienten Mäusen induziert und die klinische Entwicklung der Krankheit aufgezeichnet. 
Dafür wurden zwei unabhängige Modelle der Eosinophildefizienz herangezogen - 
∆dblGATA1 und Interleukin-5-dezimierte Mäuse. ∆dblGATA1 Mäuse gehören zu einem 
genetisch manipulierten Mausstamm, welcher eine Deletion innerhalb des GATA1 Promotors 
aufweist, die eine spezifische Dezimierung von Eosinophilen hervorruft. Interessanterweise 
war die klinische Entwicklung von EAE im Vergleich zu den Wildtypkontrollen unverändert. 
Im nächsten Schritt dezimierten wir Eosinophile durch Injektion von Antikörpern gegen den 
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Eosinophilüberlebensfaktor Interleukin-5 in Wildtypmäusen, um die Anzahl von Eosinophilen 
in der Effektorphase von EAE zu reduzieren. Im Einklang mit dem Ergebnis vom Experiment 
mit ∆dblGATA1 Mäusen war das Fortschreiten der EAE in den Eosinophil-dezimierten 
Mäusen im Vergleich zu den Mäusen, die mit dem Isotypkontrollantikörper injiziert wurden, 
unverändert. Weiterhin untersuchten wir Neuroinflammation und Demyelinisierung des 
Rückenmarks von ∆dblGATA1 Mäusen, die dem EAE Modell unterzogen wurden. 
Insbesondere die Infiltration von inflammatorischen Zellpopulationen, inklusive CD4- und 
CD8- T-Zellen, Neutrophilen und Makrophagen wurden mit Hilfe von Durchflusszytometrie 
analysiert. In Übereinstimmung mit der unveränderten klinischen EAE Entwicklung war die 
inflammatorische Zellinfiltration in ∆dblGATA1 Mäusen nicht beeinträchtigt. Des Weiteren 
analysierten wir die Expression von proinflammatorischen Zytokinen im Rückenmark von 
∆dblGATA1 Mäusen während EAE, um den inflammatorischen Status besser zu 
charakterisieren. Dabei wurden keine signifikanten Veränderungen entdeckt, was zusätzlich 
darauf hindeutet, dass Eosinophile nicht zur Neuroinflammation bei EAE beitragen. 
Schlussendlich, untersuchten wir die Demyelinisierung im Rückenmark von ∆dblGATA1 
Mäusen. Im Einklang mit der unbeeinträchtigten klinischen Entwicklung und dem 
unveränderten inflammatorischen Status, können wir keine Unterschiede in der 
Demyelinisierung des Rückenmarks von ∆dblGATA1 Mäusen im Vergleich mit 
Wildtypwurfgeschwistern feststellen. 
Zusammenfassend sind Eosinophile nicht entscheidend an der Entwicklung von EAE 
beteiligt, obwohl sie in das Rückenmark von EAE-Mäusen einwandern, dort aktiviert werden 
und degranulieren. 
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1 Introduction 
1.1 Multiple sclerosis 
Multiple sclerosis (MS) is an autoimmune neuroinflammatory demyelinating disease 
affecting about 2.5 million people world-wide. The majority of the patients are women and the 
onset of the disease is typically around 30 years of age. The pathology of the disease is 
characterized by lesions (also called plaques), which are located in the central nervous 
system (CNS), and are linked with the infiltration of immune inflammatory cells, including 
predominantly macrophages, CD8 and CD4 T cells, B cells and plasma cells. These cells 
trigger CNS inflammation that leads to the activation of resident glial cells, demyelination of 
neurons and subsequent neuroaxonal damage. As the disease progresses, the impaired 
nerve conduction in various regions of the brain and spinal cord causes a range of 
neurological dysfunctions including motor incoordination, weakness, numbness, and sensory 
and cognitive disturbances that often lead to a severe disability, thereby, substantially 
worsening the quality of life (Dendrou et al., 2015). 
Based on the clinical and magnetic resonance imaging activity and the clinical disease 
progression, MS is classified into four subtypes. The majority of the MS patients 
(approximately 85%) suffer from the relapsing-remitting MS (RRMS) characterized by attacks 
of the neurological dysfunctions (relapses) followed by periods of complete or partial 
recovery (remissions). RRMS often progresses into the secondary progressive MS (SPMS) 
distinguished by a gradual worsening of the symptoms. In approximately 10 % of the cases, 
MS shows the steady worsening phenotype already from the onset of symptoms. This MS 
subtype is classified as primary progressive MS (PPMS). The fourth subtype of MS is the 
clinically isolated syndrome (CIS) and represents the first clinical manifestation of MS but has 
not met the MS criteria of dissemination in time, yet (Lublin et al., 2014). 
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1.1.1 Risk factors for MS 
The exact cause of MS remains unknown. However, both, genetic and environmental 
risk factors were described to be involved in the disease etiology. Among the genetic risk 
factors, mostly immune system-related genes were identified. Namely, variants of human 
leukocyte antigen (HLA) class II were suggested to have the largest effect on MS 
susceptibility, possibly directing CD4 T cell specific immune response against CNS antigens. 
Moreover, genome-wide association studies revealed several susceptibility genes outside 
the HLA regions, including predominantly genes involved in T and B lymphocyte activation 
pathways, e.g. genes for cytokine receptors IL2RA and IL7R. Polymorphisms in these genes 
are probably responsible for modifying of the threshold of immune system activation rather 
that the CNS specificity (Gourraud et al., 2012, Beecham et al., 2013). Besides the genetic 
risk factors, several environmental factors were shown to play a role in MS development, 
including infections, vaccinations, other diseases, traumatic events and physical and 
biochemical agents. Out of all factors, Epstein-Barr virus infection, infectious mononucleosis 
and smoking are those proven to be associated with MS development (Belbasis et al., 2015). 
 
1.1.2 Immunopathology of MS 
It is mostly believed that the primary event of MS induction is an autoimmune T cell-
mediated attack directed against antigens in CNS, especially myelin components, which 
initiates the neurodegenerative processes mentioned above. This hypothesis is called 
„outside-in“ model of MS. However, there are also findings indicating that the 
neurodegeneration might be the initiation impulse for MS development. This “inside-out” MS 
model suggests that the neurodegenerative process generates a tissue damage that 
activates the primed immune system (Stys et al., 2012). 
According to the “outside-in” model (Figure 1), there are myelin-specific T lymphocytes 
that accidentally escaped the negative selection in the thymus. In healthy individuals, these 
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cells are controlled by mechanisms of peripheral tolerance so that their activation is 
prevented. However, when these mechanisms fail, either because of non-functional 
regulatory T cells or due to the resistance of the autoreactive T cells to the action of the 
regulatory T cells, the autoreactive T cells are activated and differentiate into effector T cell 
subsets, most importantly cytotoxic CD8 T cells and CD4 helper T cells of Th1 or Th17 
subtype. The activation can be mediated through molecular mimicry, newly formed 
autoantigens, bystander activation or antigens released from CNS. The activated effector T 
cells then activate other immune cell types, like B lymphocytes and monocytes, and infiltrate 
into CNS, crossing the blood-brain barrier, where they induce the chronic neuroinflammation 
(Dendrou et al., 2015).  
 
Figure 1 Initiation of MS (from Dendrou et al., 2015) 
A scheme presenting the initiation events of MS according to the “outside-in” model. 
 
A wide range of immune cells from both, lymphoid and myeloid lineage were shown to 
infiltrate into the brain and spinal cord in the course of MS. Among the CD4 T helper cell 
subsets, Th1 and Th17 lymphocytes are the main populations implicated in the disease 
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pathology. The typical Th1 cell-produced cytokines, interferon γ (IFNγ) and tumor necrosis 
factor (TNF), were shown to influence the disease development significantly, however, their 
exact role remains controversial. CD4 T cells isolated from MS patients express higher levels 
of IFNγ in comparison to healthy donors (Crawford et al., 2004). In accordance, a treatment 
of SPMS patients with an IFNγ-blocking antibody ameliorates the disease progression 
(Skurkovich et al., 2001) and an administration of recombinant IFNγ led to an exacerbation of 
the disease in RRMS patients (Panitch et al., 1987). Similarly, IFNγ overexpression by 
oligodendrocytes prevented disease remission in EAE, the mouse model of MS (Renno et 
al., 1998). On the other hand, studies on mice lacking IFNγ or its receptor showed that IFNγ 
is dispensable for EAE development (Ferber et al., 1996, Willenborg et al., 1996). Moreover, 
treatment of EAE mice with antibodies blocking IFNγ enhanced the disease progression 
(Billiau et al., 1988, Duong et al., 1992). Similarly, ambiguous results were reported about a 
role of TNF in MS. A blockage of TNF with a soluble receptor reduced disease severity in 
EAE (Korner et al., 1995, Korner et al., 1997a, Glabinski et al., 2004, Selmaj et al., 1995), 
indicating a possible use in MS treatment. However, a similar treatment of MS patients led to 
disease exacerbations (1999). Contradictory data were obtained when TNF knock-out mice 
were subjected to EAE since both, delayed onset (Sean Riminton et al., 1998, Korner et al., 
1997b, Kassiotis et al., 1999) and disease exacerbation (Liu et al., 1998) were observed in 
these mice. This discrepancy might be caused by opposing actions of TNF receptors since 
TNF receptor 1 signaling seems to have a pro-inflammatory effect while TNF receptor 2 acts 
in an anti-inflammatory way (Eugster et al., 1999).  
Furthermore, Th17 cells were implicated in the pathology of MS and EAE. In MS, 
numbers of Th17 cells in cerebrospinal fluid (CSF) were shown to be increased in patients 
with the disease relapse in comparison to patients in remission (Brucklacher-Waldert et al., 
2009). Moreover, interleukin-17 (IL-17), the product of Th17 cells, was suggested to disrupt 
the blood-brain barrier, thereby promoting the immune cell infiltration (Kebir et al., 2007). 
Additionally, Th17 cells were shown to infiltrate into CNS in the course of EAE, which 
appeared to be necessary for the disease development (Reboldi et al., 2009). Studies using 
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IL-17 and IL-17 receptor knock-out mice revealed the importance of this cytokine in EAE 
pathology (Gonzalez-Garcia et al., 2009, Komiyama et al., 2006). However, treatment of 
RRMS patients with an antibody against a subunit of interleukin-23 (IL-23), a Th17 
differentiation factor, failed to ameliorate disease development (Segal et al., 2008). 
In addition to CD4 T subsets, CD8 T cells were shown to contribute to the pathology of 
MS and EAE significantly. Clonally expanded CD8 T cells were found in brain lesions of MS 
patients and showed even lower heterogeneity that CD4 T cells (Babbe et al., 2000, Skulina 
et al., 2004). Moreover, clonally expanded CD8 T cells are also present in CSF and blood of 
MS patients and persist there for more than 5 years (Skulina et al., 2004). CD8 T cells are 
also well known to infiltrate CNS of mice subjected to EAE and are important for disease 
development (Camara et al., 2013, Luo et al., 2014). Moreover, the adoptive transfer of 
myelin-specific CD8 T cells induces EAE which is even more severe than EAE induced by 
the direct immunization with myelin antigen (Sun et al., 2001, Huseby et al., 2001).  
In contrast to the T cell subsets discussed above, having mainly pro-inflammatory 
roles, regulatory T cells (Tregs) were suggested to protect against MS. Importantly, there is a 
decreased proportion of Tregs in blood of patients with RRMS when compared to healthy 
individuals (Venken et al., 2008), and the frequency of Tregs is increased in blood of patients 
being in the remission (Dalla Libera et al., 2011, Peelen et al., 2011). Moreover, an impaired 
function of Tregs in MS patients was reported (Fletcher et al., 2009, Viglietta et al., 2004, 
Haas et al., 2005). EAE studies confirmed the protective role of Tregs since they accumulate 
in CNS of mice in the recovery phase of EAE and their depletion inhibits the recovery 
(McGeachy et al., 2005, O'Connor et al., 2007). 
Opposing roles in MS pathology were reported for B cells, another lymphocyte subset. 
On one hand, B cell deficiency, induced either by genetic manipulation or antibody-mediated 
depletion (anti-CD20 injection before EAE induction), led to an inhibition of disease recovery 
or to its overall exacerbation, respectively (Wolf et al., 1996, Matsushita et al., 2008), 
suggesting a regulatory role of B cells in EAE. As a mechanism, the production of interleukin-
10 (IL-10) (Fillatreau et al., 2002) and interleukin-35 (IL-35) (Shen et al., 2014), and induction 
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of Tregs (Weber et al., 2010) were suggested. On the other hand, B cells were shown to 
promote the disease development since B cell depletion induced by anti-CD20 injection after 
the disease onset was able to ameliorate EAE development (Matsushita et al., 2008, Weber 
et al., 2010). Studies by Matsushita and Weber suggest that B cells promote EAE when 
acting as the antigen-presenting cells. Moreover, B cell-derived interleukin-6 (IL-6) seems to 
contribute to the pathogenic role of B cells both, in EAE and MS (Barr et al., 2012). Indeed, B 
cell depletion appeared to be a promising therapy of MS since monoclonal antibodies against 
CD20 passed phase II and III of clinical trials for treatment of RRMS and PPMS, respectively 
(Hauser et al., 2008, Montalban et al., 2017). 
Besides the above discussed lymphoid cells, myeloid cells were also implicated in the 
pathology of MS. Neutrophils, although present in relatively low numbers in MS lesions, 
seem to contribute to the disease development. Numbers of blood neutrophils are increased 
in MS patients and they exhibit a primed phenotype (Naegele et al., 2012, Ziaber et al., 1998, 
Guarnieri et al., 1985, Hertwig et al., 2016). Furthermore, neutrophils accumulate in CSF of 
MS patients and their numbers correlate with increased levels of IL-17A that is implicated in 
the neutrophil chemoattraction (Kostic et al., 2014). Another example of a neutrophil-
attracting chemokine increased in CSF of MS patients is interleukin-8 (IL-8)  (Ishizu et al., 
2005). Moreover, expression of granulocyte colony-stimulating factor (G-CSF), the neutrophil 
activating cytokine, is upregulated in MS lesions (Lock et al., 2002) and its administration to 
MS patients can worsen the disease (Openshaw et al., 2000). The important role of G-CSF 
was confirmed in EAE model. Mice deficient for G-CSF receptor showed reduced neutrophil 
infiltration into the spinal cord and an ameliorated disease progression (Rumble et al., 2015). 
Other EAE studies demonstrated that neutrophils might contribute especially to the initiation 
of the disease when stimulating maturation of antigen presenting cells (Steinbach et al., 
2013) and facilitating the blood-brain barrier breakdown (Carlson et al., 2008, Christy et al., 
2013). 
Other myeloid populations playing a crucial role in MS pathology are macrophages and 
microglia, the macrophage-like glial cells. Although sharing many features, which also makes 
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it difficult to distinguish them in MS studies, macrophages and microglia are of a different 
origin. While CNS macrophages differentiate from bone marrow-derived monocytes, primitive 
yolk sac-derived macrophages populate CNS during the embryonic development and give 
rise to microglia (Ginhoux et al., 2010). Both of these cell types were shown to promote MS 
and EAE progression. Microglia are activated already before the disease onset and immune 
cell infiltration, proliferate and express molecules necessary for antigen presentation 
(Ponomarev et al., 2005). Later, monocytes infiltrate into CNS, differentiate to macrophages 
and promote disease progression (Ajami et al., 2011). Several studies revealed that inhibition 
of macrophages and microglia ameliorates EAE development (Bhasin et al., 2007, Wu et al., 
2013, Ponomarev et al., 2011, Goldmann et al., 2013). However, microglia were also shown 
to clear the myelin debris, thereby attenuating the neuroinflammation (Yamasaki et al., 
2014), and to produce neurotrophic factors like insulin-like growth factor 1, thereby promoting 
tissue repair (Wlodarczyk et al., 2015). These contradictory reports about the contribution of 
macrophage/microglia cells to MS could be explained by the existence of two distinct 
subtypes characterized by pro- (neurotoxic) and anti-inflammatory (neuroprotective) 
properties that are called M1 and M2 cells, respectively (Bogie et al., 2014). Indeed, there 
are studies revealing that M1 cells promote EAE development. On the other hand, M2 cells 
perform neuroprotective functions (Liu et al., 2013, Mikita et al., 2011, Moreno et al., 2014). 
 
1.1.3 Neuroaxonal damage in MS 
There are several ways how the CNS-infiltrated immune cells cause the neuroaxonal 
damage. First, T cells directly induce apoptosis in neuronal cells by expressing ligands of 
death receptors, e.g. Fas ligand (Giuliani et al., 2003) and tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) (Aktas et al., 2005), or by secretion of perforin (Nitsch et 
al., 2004). Further, activated macrophages and microglia produce reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) that cause mitochondrial dysfunction followed by 
energy deficiency in neuronal cells and these changes lead to the focal axonal degeneration 
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(Nikic et al., 2011, Fischer et al., 2012). Indeed, impaired mitochondrial function, shown as 
complex IV inactivation, was observed in the demyelinated axons within MS lesions (Mahad 
et al., 2009). Demyelination leads to upregulation and redistribution of ion channels, including 
transient receptor potential melastatin 4 (TRMP4), acid-sensing ion channel-1 (ASIC1), 
Nav1.2, Nav1.6 and Na+/Ca2+ exchanger, which in turn causes increased intracellular 
concentration of calcium and subsequent neuronal death (Craner et al., 2004, Friese et al., 
2007, Schattling et al., 2012). Further, excessive glutamate levels were proposed to play a 
role in the neuroaxonal damage in MS when increased glutamate concentrations were 
observed in the acute MS lesions in comparison to the normally appearing white matter 
(Srinivasan et al., 2005). Indeed, EAE studies revealed that activated immune cells produce 
glutamate that exerts its excitotoxic effect on neurons and oligodendrocytes (Pitt et al., 
2000). This effect is probably mediated by an increase of intracellular calcium levels to a 
toxic concentration (Nitsch et al., 2004). Furthermore, increased glutamate sensitivity of 
neurons can be induced by a proinflammatory cytokine IFNγ that forms a calcium-permeable 
complex with a subunit of glutamate receptor AMPA (alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic) (Mizuno et al., 2008). Taken together, these pathological changes lead to 
neuroaxonal damage and subsequent neuronal deficits as discussed above. 
 
1.2 Experimental autoimmune encephalomyelitis 
EAE is an animal model of MS that helps us to investigate various aspects of MS 
pathology, including neuroinflammation and demyelination (Rangachari and Kuchroo, 2013). 
It was discovered accidentally as a side effect of rabies vaccination at the end of the 19th 
century. Louis Pasteur and his colleagues injected dogs with spinal cord homogenates 
isolated from rabbits infected with attenuated rabies virus. Apart from the protection against 
the active virus, however, they often observed neurological complications in the injected 
animals, including paralysis. Later, the true EAE, used as the animal model of MS, was 
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developed immunizing rodents, rabbits and monkeys with CNS antigens emulsified in 
complete Freund’s adjuvant (CFA) (Behan and Chaudhuri, 2014). 
EAE covers a wide range of models that differ in animal species, strain and the way of 
induction. In mice, EAE can be induced by active immunization or passively by an adoptive 
transfer of myelin-specific T cells. 
1.2.1 Active EAE 
Active EAE in mice is induced by subcutaneous immunization with myelin peptides, 
typically myelin basic protein (MBP), proteolipid protein (PLP) or myelin oligodendrocyte 
glycoprotein (MOG), emulsified in CFA, that activates myelin-specific T cells and finally leads 
to  neuroinflammation and demyelination. Mice subjected to EAE exhibit ascending paralysis 
starting with tail limpness and progressing to paralysis of hind and front legs. The course of 
EAE differs according to the mouse strain and the encephalitogenic peptide used (Figure 2). 
When SJL/J mice are immunized with a peptide derived from PLP (PLP139-151), the majority of 
them develops EAE with a relapsing-remitting course resembling the relapsing-remitting MS 
in humans (Figure 2A). A similar course of EAE is induced when C57BL/6J (B6) mice are 
immunized with a low dose of MOG35-55 peptide. On the other hand, mice develop a 
monophasic form of EAE with a partial remission when immunization with a high dose of 
MOG35-55 peptide is used on C57BL/6J background (Figure 2B). When non-obese diabetic 
(NOD) mice are immunized with the same MOG fragment, they firstly exhibit a relapsing-
remitting disease with mild severity followed by a secondary worsening that resembles the 
secondary progressive MS in humans (Figure 2C). Currently, the immunization of C57BL/6J 
mice with MOG35-55 peptide is the most frequently utilized EAE model since genetic 
modifications are introduced relatively easily in this mouse strain, thereby, enabling to study 
the role of various genes and cell populations in this disease (Rangachari and Kuchroo, 
2013). 
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Figure 2 EAE models in mice (adapted from Rangachari and Kuchroo, 2013) 
A scheme of the commonest models of active EAE, showing the mouse strain and myelin peptide used and the 
subsequent disease course. 
 
1.2.2 Passive EAE 
Besides the direct immunization with myelin peptides, EAE can be also induced 
passively, i.e. by the adoptive transfer of myelin-specific T cells. This alternative method 
modeling the effector phase of the disease enables to avoid possible side effects of CFA 
injection and better mimics the real pathology of MS that is believed to start spontaneously 
with T cell attack. Originally, the myelin peptide-immunized animals were used as a source of 
the T cells, which were transferred to recipients after in vitro restimulation with a specific 
antigen (Naparstek et al., 1983). However, this method produced a clonally heterogenic T 
cell population. Later, transgenic mouse strains with T cells bearing T-cell receptor (TCR) 
specific for myelin peptides were generated, thereby, enabling to transfer T cells with 
homogeneous TCR. Additionally, these transgenic mice develop EAE spontaneously with 
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various incidences, depending on genetic background and TCR specificity, that further 
increases the possibilities for studying MS pathology (Rangachari and Kuchroo, 2013, Ben-
Nun et al., 2014). 
 
1.3 Eosinophils 
Eosinophils are a subtype of granulocytes, named according to their specific staining 
with an acidophilic dye eosin. They differentiate from hematopoietic progenitors in the bone 
marrow upon exposure to granulocyte macrophage colony-stimulating factor (GM-CSF), 
interleukin-3 (IL-3) and mainly interleukin-5 (IL-5) and are released to the blood circulation as 
fully differentiated, mature cells. They are attracted to target tissues typically following IL-5 
cytokine or chemokines of the eotaxin family. At steady state, they are predominantly present 
in the gastrointestinal tract and to a lesser extent in thymus, adipose tissue, lung, mammary 
glands and uterus where they contribute to the maintenance of tissue homeostasis. 
Regarding pathological conditions, eosinophils were described to play a crucial role as 
proinflammatory effector cells in allergic asthma, and other eosinophilic diseases including 
eosinophilic esophagitis, eosinophilic myopathy and hypereosinophilic syndrome. 
Furthermore, they significantly contribute to the immunity against infections, most importantly 
against helminths, but also against bacteria and viruses (Rosenberg et al., 2013).   
1.3.1 Immunomodulatory functions of eosinophils 
Besides the roles described above, eosinophils also modulate immune reactions 
affecting processes of both, innate and adaptive immunity, and usually promoting the Th2-
polarized immune response (Long et al., 2016). In specific conditions, eosinophils can even 
work as antigen-presenting cells (Figure 3A). In a murine model of allergic lung inflammation, 
eosinophils were shown to upregulate the expression of MHCII and costimulatory molecules 
CD80 and CD86 upon antigen challenge. They migrate to the draining lymph nodes where 
they present a processed antigen to T cells and activate them while producing interleukin-4 
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(IL-4) which promotes Th2 polarization and M2 macrophage polarization (Shi et al., 2000, 
Wang et al., 2007a). Also in humans, eosinophils can express MHCII and costimulatory 
molecules upon activation and are able to present antigen to T cells in vitro (Weller et al., 
1993, Lucey et al., 1989, Celestin et al., 2001). Eosinophils support the antigen presentation 
also indirectly by activating dendritic cells (Figure 3E). Namely, eosinophil-derived eosinophil 
peroxidase (EPX), one of the eosinophil granule proteins, activates dendritic cells and 
triggers their migration into a draining lymph node (Chu et al., 2014a). Furthermore, 
eosinophil-derived neurotoxin (EDN), another eosinophil granule protein, works as a dendritic 
cell chemoattractant and activates them through toll-like receptor 2 (TLR2) engagement 
while enhancing Th2-polarized immune response (Yang et al., 2003, Yang et al., 2008). In 
contrary, eosinophils were proposed to inhibit antigen-specific responses by production of 
transforming growth factor β (TGFβ) (Nakagome et al., 2007). Moreover, eosinophils 
increase levels of active TGFβ by production of matrix metalloprotease 9 that converts latent 
TGFβ to the active form (Chu et al., 2014b). 
Another way how eosinophils promote Th2 polarization of the immune response is 
production of indoleamine 2,3-dioxygenase (IDO) (Figure 3B). IDO is an enzyme generating 
kynurenines that induce cell death of IFNγ-producing Th1 cells but not Th2 cells (Odemuyiwa 
et al., 2004). Furthermore, eosinophils produce interleukin-25 (IL-25), thereby enhancing 
function of Th2 memory cells (Figure 3C) (Wang et al., 2007b). Finally, eosinophils were 
shown to suppress Th17 cells in small intestine by production of interleukin-1 receptor 
antagonist (Sugawara et al., 2016). 
Except of modulating T cell responses, eosinophils affect also other immune cells. In 
bone marrow and gut, eosinophils produce factors like a proliferation-inducing ligand (APRIL) 
and interleukin-6 (IL-6), thus being crucial for plasma cell survival (Chu et al., 2011, Chu and 
Berek, 2012, Chu et al., 2014b). Moreover, eosinophils were shown to be important for 
immunoglobulin A (IgA) class switching and generation of CD103+ regulatory T cells (Tregs) 
and CD103+ dendritic cells in the gut (Chu et al., 2014b).  
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Finally, released eosinophil major basic protein (eMBP) induces superoxide generation 
in neutrophils (Haskell et al., 1995) and triggers histamine release from basophils and mast 
cells (Figure 3D) (Piliponsky et al., 2003, O'Donnell et al., 1983). 
 
Figure 3 Immunomodulatory and effector functions of eosinophils (adopted from Long 
et al., 2016) 
A scheme describing interactions of eosinophils with other immune cells and effector functions of eosinophils. 
 
1.3.2 Eosinophil-derived granule proteins 
As mentioned above, eosinophils also work as effector cells, predominantly using 
degranulation in order to perform their functions. In numerous granules, they store a variety 
of preformed cytokines, chemokines, growth factors, enzymes and lipid mediators, prepared 
for a rapid degranulation after receiving a signal. Moreover, secondary granules of 
eosinophils contain cationic eosinophil-specific proteins, namely eMBP, EDN, ECP and EPX  
that are cytotoxic to pathogens but also damage the host tissues (Figure 3D) (Rosenberg et 
al., 2013). Highly basic eMBP was shown to disrupt lipid bilayers which is proposed to be the 
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mechanism of cytotoxicity (Abu-Ghazaleh et al., 1992). Further, in the context of asthma, 
eMBP induces bronchoconstriction and airway hyperactivity (Gundel et al., 1991). EDN has 
less cationic character, however, possesses RNase activity, which is necessary for its anti-
viral function (Domachowske et al., 1998b). Due to the RNase activity, EDN also exerts 
neurotoxic effect which is manifested as the Gordon phenomenon when EDN is injected 
intrathecally (Sorrentino et al., 1992). It is of note that EDN is not present in mice (Acharya 
and Ackerman, 2014). ECP is another cationic granule protein from RNase family (Acharya 
and Ackerman, 2014); however, the dependence of its cytotoxicity on the RNase activity is 
controversial (Rosenberg, 1995, Domachowske et al., 1998a). ECP was also shown to elicit 
symptoms of the Gordon phenomenon when injected intraventricularly (Fredens et al., 1982). 
EPX is the most abundant eosinophil granule protein and possesses peroxidase activity 
(Acharya and Ackerman, 2014). Interestingly, reactive oxygen species generated by EPX are 
released mainly extracellularly, unlike ROS produced by neutrophils, promoting tissue 
damage (Lacy et al., 2003). 
 
1.3.3 Mouse models of eosinophil deficiency 
In order to study a role of eosinophils in various biological processes, several mouse 
models of eosinophils deficiency were developed, using either genetic modifications or 
injection of antibodies reducing eosinophil numbers. 
As the first genetically manipulated eosinophil-deficient animal, ∆dblGATA1 mouse was 
generated. GATA-binding factor 1 (GATA1) is a transcription factor necessary for the 
development of erythroid, megakaryocytic and eosinophilic cells. However, in ∆dblGATA1 
mice, only high-affinity GATA-binding site in GATA1 promoter is removed, enabling selective 
depletion of the eosinophil lineage (Yu et al., 2002). Later, another eosinophil-deficient 
mouse strain, called PHIL or EPO-DTA, was created. In PHIL mouse, diphtheria toxin A 
chain (DTA) is expressed under control of a promoter of the eosinophil-specific EPX which 
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leads to impaired protein synthesis in eosinophils and thereby to their depletion (Lee et al., 
2004). 
As an alternative approach to genetic manipulation, injections of various antibodies 
were shown to induce eosinophil deficiency, bringing a possibility to deplete eosinophils 
inducibly. Firstly, eosinophils can be depleted by an injection of an antibody against IL-5, 
which is the main eosinophil differentiation, prosurvival, migration and activation factor. Thus, 
its blocking significantly reduces eosinophil numbers in vivo (Garlisi et al., 1999). Further, it is 
possible to deplete eosinophils by administration of antibodies against Siglec-F which is 
specifically expressed on eosinophils and its cross-linking causes their apoptosis (Song et 
al., 2009). Finally, injection of antibodies against (C-C chemokine receptor type 3) CCR3 
receptor can also lead to eosinophil depletion without affecting other cell populations 
(Grimaldi et al., 1999). 
 
1.4 Eosinophils in MS and EAE 
There is very limited knowledge about a role of eosinophils in MS and EAE. A 
microarray study of MS patients revealed an increased expression of ECP, the eosinophil 
granule protein, in the active but not inactive lesions in the brain, suggesting the presence of 
eosinophils (Lock et al., 2002). The brain infiltration of eosinophils was described in patients 
suffering from a rare rapidly progressive Marburg’s variant of MS (Elenein et al., 2011, 
Suzuki et al., 2013). However, nothing is known about their function in the disease pathology. 
In EAE, eosinophil infiltration into the spinal cord was firstly described by Gladue and 
colleagues. Moreover, they showed that blocking of the infiltration by administration of a 
leukotriene B4 antagonist ameliorated EAE development (Gladue et al., 1996). Later, the 
same group described eosinophil infiltration also into the optic nerve early in the  course of 
EAE (Milici et al., 1998). Recently, Finlay and colleagues showed that eosinophilia, induced 
by administration of helminth products, partially protects from EAE development and this 
effect is dependent on IL-33 and IL-5. Furthermore, eosinophils infiltrated brains of EAE mice 
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when treated with the helminth products but not control EAE animals (Finlay et al., 2016). 
Finally, there is a study reporting that mice lacking IL-5, the eosinophil pro-survival factor, 
develop EAE with severity comparable to their wild-type (WT) controls (Weir et al., 2003). 
Furthermore, there are reports suggesting neurotoxic effects of eosinophil products. As 
mentioned above, EDN and ECP eosinophil granule proteins were described to elicit 
symptoms of the Gordon phenomenon when injected into CNS (Fredens et al., 1982, 
Sorrentino et al., 1992). ECP was shown to have neurotoxic effect on cerebellar granule cells 
and astrocytes, inducing their apoptosis in vitro, and this mechanism was suggested to play 
a role in pathology of hypereosinophilic syndrome that affects also CNS besides other 
organs (Gleich and Leiferman, 2009, Navarro et al., 2010). Further, a role of eosinophil 
products was reported in a neuroinflammatory disease related to MS, neuromylelitis optica 
(NMO). In a mouse model of NMO, Zhang and colleagues showed that eosinophil 
degranulation causes demyelination in the spinal cord by mechanisms of antibody- and 
complement-dependent cell-mediated cytotoxity (Zhang and Verkman, 2013). Taken 
together, these data would rather implicate a negative role of eosinophils in MS and EAE. 
 
1.5 Aim of the study 
As described in the previous chapter, there are controversial data about a potential role 
of eosinophils in the pathology of MS and EAE. On one hand, there are reports suggesting 
an involvement of eosinophils in MS, since they are present in the brain in at least a subtype 
of MS. On the other hand, there are contradictory data showing both, positive and negative 
role in EAE development; and also a study suggesting no role of eosinophils in EAE. Thus, 
we attempted to solve this controversy here. For this purpose, we first induced EAE in WT 
mice and analyzed the course of eosinophil infiltration into the spinal cord. Subsequently, we 
assessed EAE development in two independent models of eosinophil deficiency with 
emphasis on the clinical development and neuroinflammation and demyelination in the spinal 
cord.
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2 Material and Methods 
2.1 Buffers and media 
 MACS buffer for myelin removal – PBS + 0.5 % BSA 
 MACS buffer for Pan T cell kit – PBS + 0.5 % BSA + 2 mM EDTA 
 FACS buffer – PBS + 0.5 % BSA + 0.1 % NaN3 
 Complete RPMI 1640 – RPMI 1640 + 10 % FBS + 1% PenStrep 
 
2.2 Mice 
Wild-type C57BL/6 mice were purchased from Charles River (Sulzfeld, Germany). 
∆dblGATA1 mice and littermate WT control on C57BL/6 background were also used. 
∆dblGATA1 mice were kindly provided by Prof. Avery August (Cornell University College of 
Veterinary Medicine, NY, USA) who backcrossed them from the original ∆dblGATA1 mouse 
strain generated on BALB/C background (Yu et al., 2002). Mice were kept in the barrier 
facility of the Medizinisch-Theoretisches Zentrum, Dresden, Germany. Animal experiments 
were approved by the Landesdirektion Sachsen, Germany. 
 
2.3 EAE induction and scoring 
Active EAE was induced as previously described (Choi et al., 2015). Eight- to twelve-
weeks old female mice were shaved at the tail base and subcutaneously injected with 200 μg 
MOG35-55 (myelin oligodendrocyte glycoprotein 35-55; peptides&elephants GmbH, Potsdam, 
Germany) emulsified in incomplete Freund’s adjuvant (Sigma, St Louis, MO, USA) containing 
500 μg inactivated Mycobacterium tuberculosis H37RA (Difco Laboratories, Detroit, MI, USA) 
and followed by intraperitoneal injection of 400 ng pertussis toxin (Merck, Darmstadt, 
Germany). The pertussis toxin injection was repeated two days later. 
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Mice were monitored daily and clinical score was determined by a blinded observer as 
follows: 0 = no clinical sign; 1 = limp tail; 2 = mild hind limb weakness; 3 = complete unilateral 
hind limb paralysis or severe weakness of both hind limbs; 4 = complete bilateral hind limb 
paralysis; 5 = four limb paralysis; 6 = death. In the case of mouse death, score 6 was 
recorded for the day of death and excluded from the rest of the scoring experiment. When 
mice started to show EAE symptoms corresponding to score 2, dry food and Solid drink gels 
(Triple A Trading, Tiel, Netherlands), substituting access to drinking water, were placed 
inside the cage.  
 
2.4 Isolation of leukocytes from spinal cord 
 The spine was excised from euthanized mice and the whole spinal cord was collected 
in PBS (after mouse anesthesia with ketamine-xylazine mixture and systemic perfusion 
through the left ventricle in order to prevent the contamination of the spinal cord infiltrate with 
circulating cells). A single-cell suspension was prepared using a 100μm cell strainer and 
myelin was removed using MACS technology in order to obtain leukocyte-enriched spinal 
cord fraction. The spinal cord suspension was incubated with Myelin Removal Beads II 
(Miltenyi Biotec, Bergisch Gladbach, Germany), that are antibodies against myelin 
conjugated to magnetic beads, and passed through a column placed in the magnetic field. 
Thus, myelin containing cells and debris were captured in the column and the leukocyte-
enriched fraction was collected and used for FACS analysis or sorting. 
 
2.5 Flow cytometry analysis and cell sorting 
The leukocyte-enriched spinal cord fraction was isolated as described above, pre-
incubated with anti-mouse CD16/32 (Fc block; BD Biosciences, Heidelberg, Germany) and 
stained in FACS buffer for 45 min with the following antibodies: anti-CD45-PE (clone 30-
F11), anti-CD11b-Alexa Fluor 488 (clone M1/70) and anti-Siglec-F-Alexa Fluor 647 (clone 
E50-2440) from BD Biosciences (Heidelberg, Germany); anti-CCR3-PE-Vio770 (clone REA 
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122), anti-CD4-APC (clone GK1.5), anti-CD8-PerCP (clone 53-6.7) from Miltenyi Biotec 
(Bergisch Gladbach, Germany); anti-CD63-APC/Cy7 (clone NVG-2), anti-Ly6G-PerCP/Cy5.5 
(clone 1A8) from BioLegend (San Diego, CA, USA); anti-F4/80-PE/Cy7 (clone BM8) from 
eBioscience (Frankfurt, Germany). Viability staining was performed using Hoechst 33258 
(Thermo Fisher Scientific, Waltham, MA, USA). 
BD FACSCanto II and BD FACSAria III instruments from BD Biosciences (Heidelberg, 
Germany) were used for flow cytometry analysis and cell sorting, respectively. Flow 
cytometry data were analyzed with FlowJo software (FlowJo, LLC, Ashland, OR, USA). 
 
2.5.1 Cell counting for flow cytometry analysis 
In order to determine the cell number of different cell populations infiltrating the spinal 
cord, the total cellularity of the leukocyte-enriched spinal cord fraction was measured. For 
this purpose, a part of the cell suspension was separated before FACS staining and diluted 
in PBS containing Hoechst 33258. Cell number was measured using MACSQuant Analyzer 
10 (Miltenyi Biotec, Bergisch Gladbach, Germany) and the total cell number of live (Hoechst 
33258-negative) singlet cells was calculated according to the dilutions that have been made. 
The obtained total cell number was than multiplied by percentages of cell populations (out of 
live singlet cells), determined by flow cytometry, and the resulting cell number was 
normalized to 100 mg of spinal cord.  
 
2.5.2 Intracellular staining for IFNγ 
In order to measure the activation of T cells in the recall response assay (chapter 2.8), 
production of IFNγ was measured after intracellular staining with FACS. At the end of the 
recall response assay, Protein Transport Inhibitor Cocktail (eBioscience, Frankfurt, Germany) 
was added into the co-culture of dendritic and T cells for 3 hours in order to inhibit the 
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secretory pathway. Thus, IFNγ was captured inside the cells and was detectable with 
intracellular staining. Afterwards, cells were collected using PBS supplied with 2mM EDTA, 
centrifuged and stained for surface markers with anti-CD4-FITC and anti-CD8-PerCP 
antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany). Then, cells were washed with 
PBS and stained with Zombie Aqua Fixable Viability Kit (BioLegend, San Diego, CA, USA) 
for 15 min in room temperature in order to distinguish dead cells during FACS analysis. Cells 
were washed with PBS supplied with 3%FBS and permeabilized using FOXP3 Staining 
Buffer Set (eBioscience, Frankfurt, Germany) for at least 40 minutes. Then, they were 
washed with Permeabilization buffer from the above mentioned buffer set and stained with 
anti-IFNγ-APC antibody (eBioscience, Frankfurt, Germany) for 30 minutes. Afterwards, cells 
were washed with Permeabilization buffer and analyzed by flow cytometry. 
 
2.6 Molecular biology methods 
In order to determine the mRNA expression of specific genes in the spinal cord tissue 
or sorted cells, RNA was isolated and transcribed to cDNA. Expression levels were 
measured in the real-time quantitative polymerase chain reaction (RT-qPCR) which allows 
for simultaneous amplification and quantification of cDNA in the gene-specific manner. 
 
2.6.1 RNA isolation 
From the spinal cord tissue, RNA was isolated using a modified Chomczynski and 
Sacchi protocol (Chomczynski and Sacchi, 1987). Briefly, a piece of tissue was homogenized 
in 500 μl of TRI Reagent (MRC, Cincinnati, OH, USA) using Precellys 24 homogenizer 
(Bertin Instruments, Montigny-le-Bretonneux, France) and centrifuged at 13000 g, 10 min, 4 
°C to remove a fat layer. Afterwards, the homogenate was transferred into a clean tube and 
100 μl of chloroform (Roth, Karlsruhe, Germany) was added. Samples were mixed, 
incubated for 3 min in room temperature and centrifuged at 13000 rpm, 10 min, 4 °C. The 
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liquid separated into three phases: the lower one containing proteins and lipids, the middle 
one containing DNA and the upper one containing RNA. The upper phase was collected into 
a new tube and mixed with 200 μl of isopropanol (VWR Chemicals, East Grinstead, UK). 
After 10 min incubation at room temperature, samples were centrifuged at 13000 rpm, for 10 
min, 4 °C so that a pellet of precipitated RNA was formed. The pellet was washed with 70% 
ethanol and dried shortly. Afterwards, it was resuspended in water and incubated at 55 °C for 
10 min to facilitate the RNA dissolution. The concentration of the isolated RNA was 
measured with the Synergy HT microplate spectrophotometer (BioTek, Bad Friedrichshall, 
Germany). 
From sorted cells, RNA was isolated using RNeasy Plus Micro Kit (Qiagen, Hilden, 
Germany). Manufacturer’s instructions were followed. 
 
2.6.2 Reverse transcription 
1 μg of RNA and all RNA isolated from the spinal cord tissue and sorted cells, 
respectively, was transcribed to cDNA using iScript cDNA Synthesis Kit (Bio-Rad 
Laboratories, Hercules, CA, USA) and Mastercycler gradient cycler (Eppendorf, Wesseling-
Berzdorf, Germany). The following protocol was used: 
 5 min at 25ºC 
 30 min at 42ºC 
 5 min at 85ºC 
 
2.6.3 Real-time quantitative PCR 
RT-qPCR was performed using SsoFast EvaGreen Supermix (Bio-Rad Laboratories, 
Hercules, CA, USA), containing DNA polymerase, dNTPs and a fluorescent nucleic acid dye. 
Besides the SsoFast EvaGreen Supermix, the reaction mixture included cDNA diluted in 
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water and gene-specific primers at a final concentration 400 nM. The primers used are listed 
in the following table. 
RPS29 fwd GAGCCGACTCGTTCCTTTCT 
RPS29 rev TTCAAGGTCGCTTAGTCCAACTTA 
18S fwd GTTCCGACCATAAACGATGCC 
18S rev TGGTGGTGCCCTTCCGTCAAT 
eMBP fwd GGAGCGTCTGCTCTTCATCT 
eMBP rev CCCCTGGAGGACACTCTTCT 
EPX fwd CTGCTTAGCTGTAGTGGGGG 
EPX rev ACGTTGCATGATGCTTTTCTGT 
ECP fwd AAGCAGACAGGGAAACATGGGT 
ECP rev TGTTCTCCTCCGACTGGTGAT 
Eotaxin-1 fwd TGCTCACGGTCACTTCCTTC 
Eotaxin-1 rev CTTGAAGACTATGGCTTTCAGGGTG 
Eotaxin-2 fwd AGGGGTCATCTTCATCACCAAG 
Eotaxin-2 rev AAGCAGCCTGGTAAAGCGT 
IFNγ fwd CTGGAGGAACTGGCAAAAGG 
IFNγ rev CTGGACCTGTGGGTTGTTGA 
IL-17A fwd CGCAAAAGTGAGCTCCAGA 
IL-17A rev TGAGCTTCCCAGATCACAG 
IL-6 fwd CCTTCCTACCCCAATTTCCAAT 
IL-6 rev AACGCACTAGGTTTGCCGAGTA 
TNF fwd AACCACCAAGTGGAGGAGCA 
TNF rev GGGTGAGGAGCACGTAGTCG 
iNOS fwd ACCTTGTTCAGCTACGCCTT 
iNOS rev CATTCCCAAATGTGCTTGTC 
IL-1β fwd ATCCCAAGCAATACCCAAAG 
IL-1β rev GTGCTGATGTACCAGTTGGG 
 
The qPCR reaction was carried out in a CFX384 Real-Time cycler (BioRad). First, DNA 
polymerase is heat-activated. Afterwards, temperature in the cycler is changed so that cycles 
of DNA denaturation, primer annealing and DNA extension are repeated. The product 
amplification is quantified in the real time as the nucleic acid dye binds to the newly formed 
double-stranded DNA and becomes fluorescent. The following protocol was used: 
1. 95 °C … 30 s 
2. 95 °C … 5 s 
3. 60 °C … 5 s 
Go to step 2. 45-times 
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4. 70 to 95 °C increase (melting curve) 
The relative gene expression was calculated by the ∆∆CT method (Livak and 
Schmittgen, 2001) and normalized to the expression of RPS29 and 18S housekeeping genes 
in the spinal cord and sorted cell samples, respectively. 
 
2.7 Eotaxin-1 ELISA 
After systemic perfusion of mice, spinal cords were collected in PBS supplied with 1x 
protease inhibitor cocktail cOmplete Mini (Roche Diagnostics, Mannheim, Germany). 
Samples were homogenized with a T10 basic Ultra-Turrax homogenizer (IKA, Staufen, 
Germany), centrifuged at 17000 g, for 30 min, at 4°C, and supernatants were collected for 
analysis. The concentration of eotaxin-1 protein was measured with Mouse CCL11/Eotaxin 
Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA). Concentration of eotaxin-1 
was normalized to the total protein amount determined by bicinchoninic acid assay (BCA) 
method (Pierce BCA Protein Assay Kit; Thermo Fisher Scientific, Waltham, MA, USA). 
 
2.8 Recall response assay 
In order to test the recall response of T cells from eosinophil-deficient and –sufficient 
mice, ∆dblGATA1 and WT mice were immunized with MOG35-55 peptide emulsified in CFA as 
described in the chapter about EAE induction (chapter 2.3). At day 7 after the immunization, 
T cells from these mice were isolated and restimulated with MOG35-55-pulsed dendritic cells 
differentiated from the bone marrow of untreated WT mice. Activation of T cells was 
measured 24 hours later as IFNγ production using intracellular staining and flow cytometry 
analysis (chapter 2.5.2). 
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2.8.1 Differentiation of dendritic cells from bone marrow 
WT mice were sacrificed and femurs and tibias were collected. Bone marrow was 
flushed out from the bones with PBS, passed through a 40 μm strainer and centrifuged at 
400 g, for 5 min, at 4 °C. Cells were seeded in complete RPMI 1640 medium supplied with 
20 ng/ml of GM-CSF (Prepro Tech, Hamburg, Germany) in suspension culture dishes. 
Medium was changed 3 days later. On day 7, floating cells, representing mainly dendritic 
cells, were harvested and used for the recall response assay. 
 
2.8.2 T cell isolation 
∆dblGATA1 and WT mice were sacrificed 7 days after the immunization with MOG35-55 
peptide. Draining lymph nodes were collected in MACS buffer and a single cell suspension 
was prepared using a 40 μm strainer. Cells were centrifuged at 400 g, for 5 min, at 4 °C and 
T cells were isolated with Pan T Cell Isolation Kit II, mouse (Miltenyi Biotec, Bergisch 
Gladbach, Germany). This kit utilizes the MACS technology. At first, cell suspension is 
stained with a cocktail of biotin-conjugated antibodies against markers of several cell 
populations except of T cells. Then, anti-biotin antibodies conjugated to magnetic beads are 
co-incubated. Finally, the stained cell suspension is applied to a column placed in magnetic 
field where non-T cell types are captured and the flow-through, containing only T cells, is 
collected. T cells isolated in this way were centrifuged at 400 g, for 5 min, at 4 °C, 
resuspended in complete RPMI 1640 medium and used for the recall response assay. 
 
2.8.3 Recall response assay 
Dendritic cells (20000/ well) were seeded in complete RPMI 1640 medium and 
incubated for 30 minutes. Afterwards they were loaded with MOG35-55 peptide at a final 
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concentration of 10 μg/ml for 4 hours. T cells were added (180000 cells/ well), co-cultured 
overnight and subsequently stained intracellularly for IFNγ (chapter 2.5.2). 
 
2.9 Luxol Fast Blue staining 
In order to analyze demyelination in the spinal cord of mice subjected to EAE, we used 
Luxol Fast Blue (LFB) MBSN stain (Sigma, St Louis, MO, USA) that binds to myelin. 
After systemic perfusion, a part of the spinal cord was dissected and incubated in 4% 
paraformaldehyde (PFA) for 1 hour at 4 °C. After washings, the tissue was transferred into 
30% sucrose (Sigma, St Louis, MO, USA) and let to sink overnight. It was embedded in OCT 
Tissue Tek (Sakura, Staufen, Germany), frozen in -80 °C and cut to 12μm sections using 
CryoStar NX50 cryostat (Thermo Fisher Scientific, Waltham, MA, USA). 
Sections were dried for 30 minutes in room temperature and OCT was washed away 
with PBS. Then, sections were fixed in methanol for 5 minutes, defatted in 1:1 
ethanol/chloroform mixture for 4 hours and hydrated in 95% ethanol for 5 minutes. Sections 
were incubated in luxol fast blue solution, composed of 0.1% luxol fast blue and 0.5% glacial 
acetic acid dissolved in 95% ethanol, at 58 °C overnight. The excess of the stain was then 
rinsed with 95% ethanol and distilled water for 1 minute each. The staining was differentiated 
in 0.05% lithium carbonate for 15 seconds followed by 70% ethanol for another 15 seconds. 
Slides were washed in distilled water and observed under a microscope. The differentiation 
steps were repeated until the white and grey matters were sharply defined. Then, sections 
were washed with 95% ethanol (1 minute), 100% ethanol (2x5 minutes) and xylene (2x5 
minutes). Slides were mounted in VectaMount Permanent Mounting Medium (Vector 
Laboratories, Peterborough, UK). 
Imaging was performed with an inverted microscope Apotome (Carl Zeiss, Jena, 
Germany) where mosaic pictures were collected. 4-6 sections from each mouse were 
analyzed using Fiji software. The amount of myelin was measured as integrated density after 
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automatic thresholding divided by area of section. Values were normalized to WT that was 
set as 100 %.  
 
2.10 Statistical analysis 
For all experiments, Mann Whitney test was used to assess the statistical significance 
of results. P values ≤0.05 were considered statistically significant (* P≤0.05, ** P≤0.01, *** 
P≤0.001). Data are presented as mean ± standard error of the mean (SEM). GraphPad 
Prism 6 software was used to calculate the statistics. 
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3 Results 
3.1 Eosinophils infiltrate into the spinal cord in the course of EAE 
In order to study neuroinflammatory processes, that are hallmark of MS pathology, 
EAE mouse model is widely used. To study a possible role of eosinophils in this disease, we 
chose the active EAE that is induced in C57BL/6 mice by immunization with a high dose of 
the peptide derived from MOG protein (MOG35-55 peptide) (Choi et al., 2015). This 
immunization protocol induces a monophasic course of the disease with the pre-onset phase 
around day 7, the onset phase around day 10, and the peak phase around day 17 after the 
immunization followed by a partial remission of symptoms.  
EAE was induced in WT mice and the infiltration of eosinophils into the spinal cord was 
assessed by FACS. In order to identify eosinophils, Siglec-F was used as a well-established 
eosinophil marker (Voehringer et al., 2007, Griseri et al., 2015). Furthermore, CD45, CD11b 
and high side scatter (SSC) were used to better recognize eosinophils by FACS (Griseri et 
al., 2015). Thus, eosinophils were determined as CD45+, SSC high, CD11b+ and Siglec-F+ 
cells. The gating strategy is show in Figure 4A. The eosinophil infiltration into the spinal cord 
was analyzed in the pre-onset (D7), onset (D10) and peak (D17) phase of EAE, and non-
immunized (healthy) mice were used as a control. There was a significant increase of 
eosinophil numbers in all three EAE time points compared to healthy mice (Figure 4B). The 
eosinophil infiltration was accompanied by an expected increase of total cell numbers which 
was also significant in all three phases of EAE (Figure 4C). Furthermore, the eosinophil 
infiltration was confirmed by RT-qPCR analysis of the expression of eosinophil granule 
proteins, namely eMBP and ECP, which are commonly used as eosinophil-specific markers 
(Rosenberg et al., 2013). The expression of ECP and eMBP in the spinal cord was 
significantly upregulated in the peak phase of EAE (Figure 4D, E). Moreover, mRNA levels of 
ECP were increased already in the onset phase of EAE (Figure 4D). Taken together, these 
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data indicate that eosinophils infiltrate into the spinal cord during EAE. Thus, we were 
interested to understand the mechanism of eosinophil chemoattraction into the spinal cord. 
 
Figure 4 Eosinophils infiltrate into the spinal cord in the course of EAE  
Wild-type female mice were immunized with MOG35-55 in CFA in order to induce EAE and leukocyte infiltrates in 
the spinal cord were analyzed at different time points. Non-immunized mice were used as controls. (A) Using 
FACS analysis, eosinophils infiltrated into the spinal cord were identified as CD45+ SSChigh CD11b+ Siglec-F+ 
cells out of live cells, determined as Hoechst-negative cells, and singlets. Representative graphs of the gating 
strategy are shown. Numbers of (B) eosinophils and (C) total cells infiltrated in the spinal cord of healthy or EAE 
mice 7, 10 and 17 days after immunization (n = 6-8/group). Relative mRNA expression of (D) eMBP and (E) ECP 
in the spinal cord of healthy or EAE mice 7, 10 and 17 days after immunization (n = 6-7/group). The expression 
was normalized to RPS29 housekeeping gene and the average expression in controls was set as 1. The P values 
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refer to comparison of control and EAE mice at different time points. ** P≤0.01, *** P≤0.001. Data are presented 
as mean ± SEM. eMBP (major basic protein), ECP (eosinophil cationic protein) 
 
3.1.1 Eotaxin-1 is a possible chemokine attracting eosinophils to 
the spinal cord in the course of EAE 
Eotaxins are typical eosinophil chemoattractants, driving CCR3 positive eosinophils to target 
tissues under homeostatic or inflamed conditions. In context of inflammation, eotaxin-1 and -
2 are necessary for the eosinophil infiltration to lung of mice subjected to a murine model of 
asthma (Pope et al., 2005). To identify a possible mechanism of eosinophil recruitment in our 
model we analysed eotaxins in the spinal cord during EAE. As eotaxin-3 is a pseudogene in 
mice (Pease and Williams, 2013), we analyzed mRNA levels of eotaxin-1 and -2 in the spinal 
cord of EAE and control mice. Expression of eotaxin-1, but not eotaxin-2, was significantly 
increased in the onset and peak phase of the disease (Figure 5A, B). There was a trend for 
eotaxin-2 to be increased at the onset of EAE (Figure 5B). In order to confirm the eotaxin-1 
upregulation at the protein level, we used ELISA to measure eotaxin-1 in homogenates of 
spinal cords isolated from EAE and control mice. Since mRNA expression of eotaxin-1 was 
predominantly upregulated in the onset phase of EAE (D10) we chose this time point to 
analyze its protein levels. Concentration of eotaxin-1 was significantly increased at this time 
point, as compared to the spinal cords from control mice (Figure 5C). These data suggest 
that eotaxin-1 is a possible chemoattractant for spinal cord-infiltrating eosinophils in the 
course of EAE. However, this mechanism requires further confirmation, for instance by using 
an eotaxin-1 blocking agent or eotaxin-1 receptor knock-out mice. 
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Figure 5 Eotaxin-1 concentration increases in the spinal cord of EAE mice 
Wild-type mice were immunized with MOG35-55 in CFA in order to induce EAE and eotaxin levels in the spinal cord 
were analyzed at different time points. Non-immunized mice were used as controls. Relative mRNA expression of 
(A) eotaxin-1 and (B) eotaxin-2 in the spinal cord of healthy or EAE mice 7, 10 and 17 days after immunization (n 
= 6-7/group). The expression was normalized to RPS29 housekeeping gene. (C) Protein levels of eotaxin-1 in 
spinal cord homogenates from healthy or EAE mice were analyzed by ELISA 10 days after immunization. 
Eotaxin-1 concentration was normalized to the total protein amount (n = 4-5/group). The P values refer to 
comparison of control and EAE mice at different time points. * P≤0.05, ** P≤0.01. Data are presented as mean ± 
SEM. 
 
3.2 Spinal cord eosinophils are activated and degranulate during 
EAE 
Since eosinophils accumulate in the spinal cord of EAE mice (Figure 4), we proceeded 
to the analysis of their activation status. For this purpose, we chose CD11b integrin of which 
increased surface expression has been reported as a marker of eosinophil activation in a 
mouse model of colitis (Griseri et al., 2015). Interestingly, its expression by spinal cord 
eosinophils, measured by FACS, was significantly increased in the onset and peak phase of 
EAE when compared to spinal cord eosinophils from healthy mice (Figure 6A). The activation 
of the spinal cord eosinophils was further tested by FACS analysis of CCR3 receptor 
expression. Decrease of CCR3 expression on eosinophils has been shown as a marker of 
activation in a mouse model of lung infection (Voehringer et al., 2007). Indeed, surface 
expression of CCR3 on spinal cord eosinophils gradually decreased in the course of EAE. 
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(Figure 6B). Since there is the downregulation of CCR3 expression on eosinophils during 
EAE and we have noticed two distinct populations of eosinophils in the spinal cord of EAE 
mice differing in the expression of CCR3 (Figure 4A), we questioned whether there is a 
difference in the expression of eosinophil granule toxins between these two populations 
which might help us to better understand the activation status of eosinophils in EAE. For this 
purpose, CCR3-possitive and –negative eosinophils were sorted from the spinal cord of EAE 
mice in the peak phase of the disease and the expression of the eosinophil granule proteins 
eMBP, ECP and EPX was analyzed by RT-qPCR. Interestingly, expression of all three 
proteins was significantly higher in CCR3-negative eosinophils (Figure 6C-E). These results 
indicate that during the activation of eosinophils (characterized by CCR3 downregulation) 
they upregulate expression of their granule toxins, which might contribute to the pathology of 
EAE. 
 
Figure 6 Spinal cord-infiltrating eosinophils are activated in EAE 
Wild-type mice were immunized with MOG35-55 in CFA in order to induce EAE and leukocyte infiltrates in the 
spinal cord were analyzed at different time points. Non-immunized mice were used as controls. The expression of 
(A) CD11b and (B) CCR3 on eosinophils determined as CD45+ SSChigh CD11b+ Siglec-F+ cells by FACS in 
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healthy or EAE mice 7, 10 and 17 days after immunization. The expression is presented as MFI and normalized 
to healthy controls (n =4-6/group). CCR3+ and CCR3- eosinophils from the spinal cord of EAE mice at the peak 
of the disease were sorted by FACS. Relative mRNA expression of (C) eMBP, (D) ECP and (E) EPX was 
analyzed by qPCR and normalized to 18S expression (n =7-10/group). * P≤0.05, ** P≤0.01, *** P≤0.001. Data 
are presented as mean ± SEM. MFI (median of fluorescence intensity), eMBP (major basic protein), EPX 
(eosinophil peroxidase), ECP (eosinophil cationic protein), ND (not detected) 
 
As we found that eosinophils are activated in EAE and that the expression of their 
granule proteins is upregulated, we were further interested to study whether eosinophils 
degranulate in the spinal cord of EAE mice. Therefore, we analyzed eosinophil degranulation 
using FACS by measuring their side scatter parameter which describes the granularity of 
cells. Thus, SSC decrease corresponds to the loss of granules and, thereby, is a measure of 
degranulation. Indeed, SSC of spinal cord eosinophils was significantly decreased during all 
stages of EAE when compared with healthy mice (Figure 7A). In order to confirm the 
degranulation, we used another marker, tetraspanin CD63. Increased surface expression of 
CD63 is a marker of degranulation of gut eosinophils in a mouse colitis model (Griseri et al., 
2015). In agreement with the decreased SSC, the percentage of CD63-positive eosinophils 
was significantly increased in the spinal cord of EAE mice in the peak of the disease (Figure 
7B). Therefore, our data showed that eosinophils likely degranulate in the spinal cord of EAE 
mice. 
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Figure 7 Spinal cord-infiltrating eosinophils degranulate in EAE 
Wild-type mice were immunized with MOG35-55 in CFA in order to induce EAE and leukocyte infiltrates in the 
spinal cord were analyzed at different time points. Non-immunized mice were used as controls. (A) SSC median 
of spinal cord eosinophils from control or EAE mice 7, 10 and 17 days after immunization. Data were normalized 
to the healthy controls (n =4-6/group). (D) Percentage of spinal cord eosinophils expressing CD63 in control and 
EAE mice 17 days after immunization determined by FACS (n =4-6/group). ** P≤0.01. Data are presented as 
mean ± SEM. SSC (side scatter) 
 
3.3 Eosinophils are dispensable for EAE development 
Since we demonstrated that eosinophils infiltrate into the spinal cord during EAE 
(Figure 4) and they are activated and degranulate therein (Figure 6, Figure 7), suggesting a 
potential role in EAE pathology, we were interested whether they are necessary for disease 
development. For this purpose, we used two independent models of eosinophil deficiency: 
∆dblGATA1 mice (Yu et al., 2002) and anti-IL-5 antibody-mediated eosinophil depletion 
(Garlisi et al., 1999). At first, ∆dblGATA1 mice and their littermate controls were subjected to 
EAE using the immunization protocol described above for WT mice, and the clinical 
development was assessed (for more details regarding the clinical scoring see chapter 2.3). 
Interestingly, we did not observe any significant changes in EAE severity when comparing 
∆dblGATA1 mice with their eosinophil-sufficient controls as shown in an EAE development 
graph (Figure 8A) and as area under the curve (AUC) (Figure 8B). Second, wild-type mice 
were injected intraperitoneally with an antibody against IL-5 or its isotype control at day 5 and 
8 after the EAE induction in order to deplete eosinophils in the effector phase of EAE when 
the eosinophil infiltration into the spinal cord was the most prominent (Figure 4). Confirming 
the result from ∆dblGATA1 mice, there was no difference in EAE severity between 
eosinophil-depleted and isotype-injected mice as shown again in both, the EAE development 
graph (Figure 8C) and AUC representation (Figure 8D). Taken together, EAE clinical scoring 
experiments showed that eosinophils are dispensable for EAE development in two 
independent models of eosinophil deficiency. 
 
 45 
 
Figure 8 Eosinophils are not necessary for EAE development 
Female ∆dblGATA1 mice and their littermate controls were immunized with MOG35-55 in CFA in order to induce 
EAE and the clinical development was scored by a blinded observer (n=9-11/group). (A) Mean clinical score was 
plotted in the time course and statistical analysis was performed for every day separately. (B) Area under the 
curve was calculated from the data in (A). Female WT mice were immunized with MOG35-55 in CFA in order to 
induce EAE and intraperitoneally injected with anti-IL-5 antibody or isotype control (10 μg/mouse) at day 5 and 8 
after the immunization (n=10/group). The clinical development of EAE was scored by a blinded observer. (C) 
Mean clinical score was plotted in a time course and statistical analysis was performed for every day separately. 
(D) Area under the curve was calculated from the data in (C). Data are presented as mean ± SEM. AUC (area 
under the curve) 
 
3.3.1 No difference in inflammation in the spinal cord of ∆dblGATA1 
mice 
In order to further assess a potential functional contribution of eosinophils in EAE 
pathology, we analyzed the infiltration of several inflammatory cell populations into the spinal 
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cord of eosinophil-deficient and –sufficient mice at the peak of EAE (day 17). For this 
purpose, ∆dblGATA1 mice were chosen since they are the more specific model of eosinophil 
deficiency. The spinal cord infiltrating cells were analyzed using FACS. Leukocyte-enriched 
fraction of the spinal cord homogenate was prepared and two separated FACS stainings for 
myeloid and lymphoid cells were performed. Eosinophils were identified as CD45+ SSChigh 
CD11b+ Siglec-F+ Ly6Glow F4/80int cells (Figure 9A), neutrophils as CD45+ CD11b+ F4/80- 
Ly6G+ cells (Figure 9B), macrophages as CD45+ CD11b+ Ly6G- F4/80+ CD45high cells 
(Figure 9B), CD4 T cells as CD45+ CD8- CD4+ cells (Figure 9C) and CD8 T cells as CD45+ 
CD4- CD8+ cells (Figure 9C). 
 
Figure 9 Gating strategy for inflammatory cell FACS analysis 
Representative FACS plots show gating strategy for the identification of (A) eosinophils, (B) neutrophils, 
macrophages and (C) CD4 and CD8 T cells infiltrating the spinal cord of WT control mice subjected to EAE. 
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We did not observe any significant difference in the numbers of total CD45+ cells 
(Figure 10A), CD4 T cells (Figure 10B), CD8 T cells (Figure 10C), neutrophils (Figure 10D) 
and macrophages (Figure 10E) infiltrating the spinal cord of ∆dblGATA1 and WT control 
mice at the peak of the disease. As expected, there were nearly no eosinophils detected in 
∆dblGATA1 mice in contrast to their WT controls (Figure 10F). In accordance with the 
scoring experiments presented above, these mice had a comparable clinical score (Figure 
10G).  
 
Figure 10 No difference in inflammatory cell infiltration in ∆dblGATA1 mice 
Female ∆dblGATA1 mice and their littermate controls were immunized with MOG35-55 in CFA in order to induce 
EAE. Numbers of spinal cord-infiltrated (A) CD45+, (B) CD4 T and (C) CD8 T cells, (D) neutrophils, (E) 
macrophages and (F) eosinophils were analyzed by FACS at day 17 after EAE induction. (G) Clinical score of the 
analyzed mice at day 17 after EAE induction (n=6-7/group). ** P≤0.01. Data are presented as mean ± SEM. 
 
In order to further analyze the inflammatory status of the spinal cord in ∆dblGATA1 and 
WT mice, expression analysis of inflammatory molecules (IFNγ, IL-17A, IL-6, TNF, iNOS, IL-
1β) in the spinal cord was performed in the peak phase of EAE. We did not observe any 
significant difference in any of the assessed molecules (Figure 11), showing that also the 
cytokine milieu is not changed in ∆dblGATA1 mice. In order to verify eosinophil deficiency, 
expression of eMBP, one of the eosinophil markers, was also analyzed by RT-qPCR. Indeed, 
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mRNA levels of eMBP were significantly downregulated in ∆dblGATA1 mice as compared to 
their littermate controls (Figure 11). 
Taken together, these data show that there is no difference in the inflammatory status 
of the spinal cord when comparing eosinophil-deficient and –sufficient mice subjected to EAE 
which is in agreement with their identical clinical scores during EAE development (Figure 8). 
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Figure 11 No difference in proinflammatory cytokines in ∆dblGATA1 mice 
Female ∆dblGATA1 mice and their littermate controls were immunized with MOG35-55 in CFA in order to induce 
EAE. mRNA levels of IFNγ, IL-17A, IL-6, TNF, iNOS, IL-1β and eMBP in the spinal cord were analyzed using RT-
qPCR at day 17 after EAE induction (n=6-7/group). The expression was normalized to RPS29 housekeeping 
gene. *** P≤0.001. Data are presented as mean ± SEM. 
 
3.3.2 No difference in demyelination in the spinal cord of 
∆dblGATA1 mice 
Not only neuroinflammation but also demyelination is an important hallmark of EAE 
pathology and these two aspects are interconnected (Dendrou et al., 2015). Thus, we tested 
the degree of demyelination in the spinal cord of ∆dblGATA1 and WT mice at the peak of 
EAE using LFB staining of myelin. In accordance with no change in neuroinflammation and 
clinical development, we also did not observe any difference in demyelination (Figure 12) 
further suggesting that eosinophil deficiency does not affect EAE development. 
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Figure 12 Demyelination in ∆dblGATA1 mice 
Female ∆dblGATA1 mice and their littermate controls were immunized with MOG35-55 in CFA in order to induce 
EAE. At day 17 after immunization, 12μm spinal cord cryosections were stained with LFB for myelin levels 
measurement (n=3-5/group). (A) quantification, (B) representative pictures. Scale bar 500 μm. Data are 
presented as mean ± SEM. 
 
3.3.3 No difference in recall response in ∆dblGATA1 mice 
In order to complete the analysis of a possible impact of eosinophils on EAE 
development, the initiation phase of EAE was investigated in ∆dblGATA1 mice. These mice 
and their littermate controls were immunized with MOG35-55 peptide in order to induce EAE. 
They were sacrificed 7 days later and a recall response of T cells isolated from draining 
lymph nodes to the MOG35-55 antigen was analyzed. The isolated T cells were co-cultured 
with MOG35-55-pulsed dendritic cells differentiated from bone marrow cells isolated from 
untreated WT mice. In order to measure the activation of T cells, IFNγ production was 
assessed by intracellular staining followed by FACS analysis. No difference in the activation 
of CD4 and CD8 T cells was found since the percentage of IFNγ-producing CD4 and CD8 T 
cells, respectively, was not changed in ∆dblGATA1 mice (Figure 13A, B).These data show 
that eosinophil deficiency does not affect the initiation phase of EAE. 
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Figure 13 No difference in recall response in ∆dblGATA1 mice 
Female ∆dblGATA1 mice and their littermate controls were immunized with MOG35-55 in CFA. At day 7, T cells 
isolated from draining lymph nodes were co-cultured with MOG35-55-pulsed dendritic cells for 24 hours. Surface 
expression of CD4 and CD8 and intracellular expression of IFNγ were analyzed by FACS (n=6/group). Data are 
presented as mean ± SEM. 
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4 Discussion 
MS is an autoimmune neuroinflammatory demyelinating disease, afflicting 2.5 million 
people worldwide, causing a variety of neurological problems often leading to a permanent 
use of wheel chair. Moreover, the typical onset of the disease is around 30 years of age, 
thus, the quality of life in the productive age is seriously affected. Unfortunately, the 
pathology and especially the cause of MS are not well characterized and therefore the 
successfulness of the treatment is limited. Although, the cause of the disease is 
controversial, it is mostly believed that the launching event is a dysregulation of immune 
system, which is followed by infiltration of immune cells into CNS and subsequent 
neuroinflammation (Dendrou et al., 2015). Many immune cell types were described to be 
involved in the immunopathology of MS, playing either positive or negative roles. However, 
there is only very limited information about a possible role of eosinophils in this disease. 
Thus, we were encouraged to investigate it in order to reveal new mechanisms of MS 
pathology and, maybe, to contribute to development of a more efficient MS treatment. 
In order to study a role of eosinophils in MS, we employed its mouse model EAE that 
mimics both, the neuroiflammatory and demyelinating aspects of the disease. At first, we 
assessed whether there is eosinophil infiltration into CNS of EAE-subjected mice. For this 
purpose, EAE was induced in WT mice and the eosinophil numbers in the spinal cord were 
analyzed in the course of the disease and compared to healthy controls. In the present study, 
we showed that eosinophils infiltrate into the spinal cord during EAE and, moreover, that they 
are activated and degranulate there. Additionally, concentration of eotaxin-1, the eosinophil 
chemoattractant, was increased in EAE mice, suggesting eotaxin-1-mediated mechanism of 
eosinophil infiltration. Further, we induced EAE in two independent mouse models of 
eosinophil deficiency, ∆dblGATA1 and IL-5-depleted mice, and observed the clinical 
symptoms. Interestingly, we found that eosinophils are dispensable for EAE development in 
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both models. We chose ∆dblGATA1 mice, as the more specific model, and analyzed these 
mice in detail with regards to different aspects of EAE pathology. In accordance with the 
comparable clinical course, we did not observe any difference in the infiltration of various 
immune cell populations into the spinal cord, or in the proinflammatory molecule expression 
and demyelination. Furthermore, T cells isolated from ∆dblGATA1 mice behaved similarly in 
the recall response assay, indicating that the immunization phase was not affected by the 
eosinophil deficiency that is also in accordance with the results of the scoring experiments. 
Recently, Finlay and colleagues reported that eosinophilia induced by an injection of 
helminth products has a protective effect against EAE development (Finlay et al., 2016). In 
contrast, we show herein that eosinophil deficiency does not influence EAE development. A 
possible explanation for this discrepant result is that, in their study, eosinophils acquire a 
regulatory phenotype due to the helminth products injection, thereby ameliorating EAE. 
Indeed, in vitro differentiated eosinophils from bone marrow without any additional treatment 
were not able to reduce EAE severity when transferred into EAE mice. In contrast, when they 
transferred eosinophils from mice treated with interleukin-33 (IL-33), a mediator of the 
helminth product-induced eosinophilia, development of EAE in recipient mice was impaired 
(Finlay et al., 2016). In accordance with the hypothesis that eosinophils with different 
phenotypes might play different roles in the immunity, Mesnil and colleagues showed that 
lung resident eosinophils have a different character than eosinophils infiltrating the lung after 
allergic stimulus. They propose that resident eosinophils, but not the infiltrated ones, possess 
a regulatory phenotype, as shown by transcriptome analysis, and are able to reduce immune 
response by inhibiting dendritic cell maturation (Mesnil et al., 2016). Thus, it might be that 
only eosinophils that have been polarized to a specific phenotype (e.g. after a parasitic 
infection) are capable to affect EAE development.  
Another study assessing a role of eosinophils in EAE was performed by Gladue and 
colleagues. They were the first who reported eosinophil infiltration into the spinal cord of EAE 
mice. Further, they proposed that a treatment of EAE mice with a leukotriene B4 antagonist 
reduces the eosinophil infiltration and EAE severity. Moreover, they claimed that the 
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lymphocyte infiltration remains unaffected by this treatment and, therefore, that the effect is 
eosinophil specific (Gladue et al., 1996). However, leukotriene B4 is known to have a broad 
range of proinflammatory effects, including recruitment of immune cells and their activation 
(Le Bel et al., 2014). Therefore, it is likely that other cell types besides eosinophils were 
affected by the leukotriene B4 antagonist. Moreover, Gladue et al. induced EAE by the 
adoptive transfer of encephalogenic T cells into SJL mice (Gladue et al., 1996), which is a 
model different from ours. Thus, different experimental conditions may also account for 
different findings between this previous study and ours. 
Weir et al. showed that IL-5 deficiency does not affect EAE development, using IL-5 
knock-out mice (Weir et al., 2003), which is in agreement with our results, especially with the 
experiment using IL-5 blockade to deplete eosinophils. 
Zhang and colleagues reported that eosinophil degranulation causes demyelination in 
the spinal cord in a mouse model of NMO (Zhang and Verkman, 2013). However, although 
we see that eosinophils infiltrate into the spinal cord and likely degranulate therein during 
EAE, we did not observe any difference in demyelination between eosinophil-deficient and –
sufficient mice. A possible explanation for this disagreement is that the mechanisms of 
antibody- and complement-dependent cell-mediated cytotoxity, described in NMO, do not 
occur in EAE. Another possible explanation is that the contribution of eosinophil 
degranulation to the overall demyelination is minor and, thus, the impact is not observable in 
eosinophil-deficient mice. 
There are several reports that eosinophils can support initiation of an antigen-specific 
immune response, namely antigen presentation, either directly, when acting as antigen 
presenting cells, or indirectly by promoting dendritic cell maturation and migration. In 
contrast, there is a study proposing that eosinophils inhibit antigen-induced immune 
responses by TGFβ-mediated suppression of CD4 T cells (see chapter 1.3.1). In the present 
thesis, we show that eosinophil deficiency did not affect antigen-specific T cell activation, 
since we did not observe any difference in antigen-specific in vitro restimulation of T cells 
isolated from MOG-immunized ∆dblGATA1 and control mice. In accordance with our results, 
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Weir and colleagues also did not see any abnormalities in recall response of T cells isolated 
from MOG-immunized IL-5-deficient mice (Weir et al., 2003). The discrepancy in reports 
describing the role eosinophils in the initiation of antigen-specific immune response might 
result from use of different mouse strains and immunization models. While we and Weir et al. 
use mice in a C57BL/6 background immunized with MOG in order to induce EAE, the 
majority of the other studies used mice with BALB/c background subjected to a model of 
allergic inflammation. 
Furthermore, we show a significant upregulation of eotaxin-1, the eosinophil 
chemoattractant, at the peak of EAE but most substantially at the onset of the disease. 
Additionally, expression of eotaxin-2, another eosinophil chemoattractant, was increased at 
the onset of EAE although not significantly. In a mouse model of asthma, it was shown that 
expression of eotaxin-1 and -2 is necessary for eosinophil recruitment into lung which is 
mediated by CCR3 receptor expressed on eosinophils (Pope et al., 2005). Thus, we propose 
that the eotaxin-1/2-CCR3 axis is responsible for eosinophil recruitment also into the spinal 
cord. In the future, this hypothesis will be tested using CCR-3 knock-out mice subjected to 
EAE. 
In conclusion, we present herein that eosinophils infiltrate into the spinal cord in the 
course of EAE and they are activated and degranulate there. We suggest that the infiltration 
is mediated by eotaxins and their receptor CCR3. Finally, we show that eosinophils are 
dispensable for EAE development in our experimental setting. However, as described in 
literature, eosinophils can play a protective role against EAE development when they acquire 
a regulatory phenotype. This is a phenomenon that should be further studied in the context of 
MS pathogenesis. 
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